- Home
- OPFI vs SCPH Comparison
OPFI vs SCPH Comparison
Compare OPFI & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- SCPH
- Stock Information
- Founded
- OPFI 2009
- SCPH 2013
- Country
- OPFI United States
- SCPH United States
- Employees
- OPFI N/A
- SCPH N/A
- Industry
- OPFI Finance: Consumer Services
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- SCPH Health Care
- Exchange
- OPFI Nasdaq
- SCPH Nasdaq
- Market Cap
- OPFI 300.3M
- SCPH 299.0M
- IPO Year
- OPFI N/A
- SCPH 2017
- Fundamental
- Price
- OPFI $11.12
- SCPH $5.64
- Analyst Decision
- OPFI Buy
- SCPH Buy
- Analyst Count
- OPFI 2
- SCPH 3
- Target Price
- OPFI $11.75
- SCPH $12.00
- AVG Volume (30 Days)
- OPFI 970.2K
- SCPH 2.3M
- Earning Date
- OPFI 11-06-2025
- SCPH 11-12-2025
- Dividend Yield
- OPFI 9.00%
- SCPH N/A
- EPS Growth
- OPFI N/A
- SCPH N/A
- EPS
- OPFI N/A
- SCPH N/A
- Revenue
- OPFI $320,831,000.00
- SCPH $49,969,000.00
- Revenue This Year
- OPFI $116.69
- SCPH $108.95
- Revenue Next Year
- OPFI $9.90
- SCPH $78.30
- P/E Ratio
- OPFI N/A
- SCPH N/A
- Revenue Growth
- OPFI 31.26
- SCPH 107.79
- 52 Week Low
- OPFI $4.16
- SCPH $1.94
- 52 Week High
- OPFI $17.73
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- OPFI 58.86
- SCPH 64.10
- Support Level
- OPFI $10.03
- SCPH $4.33
- Resistance Level
- OPFI $10.59
- SCPH $5.62
- Average True Range (ATR)
- OPFI 0.42
- SCPH 0.04
- MACD
- OPFI 0.16
- SCPH -0.00
- Stochastic Oscillator
- OPFI 84.28
- SCPH 96.43
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.